Literature DB >> 6260215

Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor and a hypotensive lipid) by cholinephosphotransferase in various rat tissues.

W Renooij, F Snyder.   

Abstract

The unique alkyl phospholipid, 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, has been reported to exhibit powerful antihypertensive activity (Blank, M.L., Snyder, F., Byers, L.W., Brooks, B. and Muirhead, E.E. (1979) Biochem. Biophys. Res. Commun. 90, 1194-1200) and appears to be an extremely potent platelet-activating factor (Demopoulos, C.A., Pinckard, R.N. and Hanahan, D.J. (1979) J. Biol. Chem. 254, 9355-9358). In the present study, microsomal preparations from several rat tissues were found to catalyze the synthesis of 1-alkyl-1-acetyl-sn-glycero-3-phosphocholine by 1-alkyl-2-acetyl-sn-glycerol:CDPcholine cholinephosphotransferase reaction. Optimal conditions to measure enzyme activity were established. A subcellular survey of this cholinephosphotransferase activity showed that the enzyme was of microsomal origin. Enzyme activity was found in microsomes from several tissues; however, spleen has the highest activity of the tissues examined. Three different species of 1-alkyl-2-acetyl-sn-glycerol were all found to be substrates. The 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine synthesized in the microsomes could be hydrolyzed by adding the 100,000 x g supernatant fraction to the incubation medium. The optimum pH for formation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine was 8.0, which was different from the pH optimum of 8.5 observed for the long-chain diacylglycerol cholinephosphotransferases. Activity of cholinephosphotransferase towards 1-alkyl-2-acetyl-sn-glycerol was slightly enhanced and stabilized by dithiothreitol, whereas the activity towards a diacylglycerol was inhibited by dithiothreitol. The possible involvement of two different enzymes in the conversion of 1-alkyl-2-acetyl-sn-glycerol and diacylglycerol to their respective phospholipid products is discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6260215     DOI: 10.1016/0005-2760(81)90182-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  27 in total

1.  Calcium-dependent biosynthesis of platelet-activating factor by submandibular gland cells.

Authors:  T Dohi; K Morita; S Kitayama; A Tsujimoto
Journal:  Biochem J       Date:  1991-05-15       Impact factor: 3.857

2.  Mechanism of lysophosphatidylcholine accumulation in the ischemic canine heart.

Authors:  T Mock; R Y Man
Journal:  Lipids       Date:  1990-07       Impact factor: 1.880

3.  Platelet-activating factor (PAF-acether) formation in rat basophilic leukemia cells stimulated by ionophore A23187.

Authors:  M Hirafuji; J F Nave
Journal:  Agents Actions       Date:  1987-10

Review 4.  Metabolic processing of PAF.

Authors:  F Snyder
Journal:  Clin Rev Allergy       Date:  1994

Review 5.  Platelet-activating factor: the biosynthetic and catabolic enzymes.

Authors:  F Snyder
Journal:  Biochem J       Date:  1995-02-01       Impact factor: 3.857

Review 6.  Biology and biochemistry of platelet-activating factor.

Authors:  J T O'Flaherty; R L Wykle
Journal:  Clin Rev Allergy       Date:  1983-09

7.  Formation of diacyl and alkylacyl glycerophosphocholine in rabbit alveolar macrophages.

Authors:  T Sugiura; N Sekiguchi; Y Nakagawa; K Waku
Journal:  Lipids       Date:  1987-08       Impact factor: 1.880

8.  Ether lipid content and fatty acid distribution in rabbit polymorphonuclear neutrophil phospholipids.

Authors:  H W Mueller; J T O'Flaherty; R L Wykle
Journal:  Lipids       Date:  1982-02       Impact factor: 1.880

9.  Metabolism of platelet-activating factor by blood platelets and plasma.

Authors:  I Alam; J B Smith; M J Silver
Journal:  Lipids       Date:  1983-08       Impact factor: 1.880

10.  Inhibition of PAF synthesis by stimulated human polymorphonuclear leucocytes with cloricromene, an inhibitor of phospholipase A2 activation.

Authors:  E Ribaldi; A M Mezzasoma; E Francescangeli; M Prosdocimi; G G Nenci; G Goracci; P Gresele
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.